Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANL NASDAQ:BTMD NASDAQ:ELDN NASDAQ:LRMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$1.46+1.7%$1.58$1.10▼$3.89$52.77M-0.956,641 shs4,210 shsBTMDbiote$3.89-4.4%$4.01$3.04▼$7.34$222.67M1.2184,602 shs120,114 shsELDNEledon Pharmaceuticals$3.38+7.3%$3.16$2.38▼$5.54$188.63M-0.15675,391 shs648,913 shsLRMRLarimar Therapeutics$3.44-0.6%$2.99$1.61▼$9.50$221.54M0.931.06 million shs1.16 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye+1.75%+1.04%-7.62%-24.02%-58.43%BTMDbiote-4.42%-9.95%-7.16%+11.78%-50.95%ELDNEledon Pharmaceuticals+7.30%-6.63%+10.46%+2.11%+14.97%LRMRLarimar Therapeutics-0.58%-11.34%+10.61%+15.82%-59.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANLAdlai Nortye1.7465 of 5 stars3.05.00.00.00.00.00.0BTMDbiote2.948 of 5 stars3.53.00.00.00.63.31.3ELDNEledon Pharmaceuticals2.1745 of 5 stars3.52.00.00.02.91.70.0LRMRLarimar Therapeutics2.246 of 5 stars3.62.00.00.03.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 2.00Hold$9.00518.56% UpsideBTMDbiote 3.00Buy$8.00105.66% UpsideELDNEledon Pharmaceuticals 3.00Buy$10.00195.86% UpsideLRMRLarimar Therapeutics 3.11Buy$18.50437.79% UpsideCurrent Analyst Ratings BreakdownLatest ANL, BTMD, LRMR, and ELDN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/25/2025ELDNEledon PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/24/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/24/2025LRMRLarimar TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.006/24/2025LRMRLarimar TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.006/18/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$9.006/2/2025ANLAdlai NortyeHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M10.74N/AN/A$0.69 per share2.11BTMDbiote$199.38M1.07$0.73 per share5.31($2.78) per share-1.40ELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.98 per shareN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$51.87MN/A0.00N/AN/AN/AN/AN/A8/8/2025 (Estimated)BTMDbiote$3.16M$0.616.387.20N/A10.93%-19.44%20.12%8/6/2025 (Estimated)ELDNEledon Pharmaceuticals-$36.18M-$2.10N/AN/AN/AN/A-79.54%-41.62%8/18/2025 (Estimated)LRMRLarimar Therapeutics-$80.60M-$1.49N/AN/AN/AN/A-52.48%-46.08%8/6/2025 (Estimated)Latest ANL, BTMD, LRMR, and ELDN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025ELDNEledon Pharmaceuticals-$0.23N/AN/AN/AN/AN/A8/6/2025Q2 2025BTMDbiote$0.06N/AN/AN/A$49.52 millionN/A8/6/2025Q2 2025LRMRLarimar Therapeutics-$0.4877N/AN/AN/AN/AN/A5/14/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28-$0.08+$0.20-$0.08N/AN/A5/7/2025Q1 2025BTMDbiote$0.06$0.08+$0.02$0.37$47.25 million$48.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai Nortye0.021.411.41BTMDbioteN/A1.421.14ELDNEledon PharmaceuticalsN/A13.9013.91LRMRLarimar TherapeuticsN/A7.487.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%BTMDbiote21.68%ELDNEledon Pharmaceuticals56.77%LRMRLarimar Therapeutics91.92%Insider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/ABTMDbiote24.00%ELDNEledon Pharmaceuticals12.30%LRMRLarimar Therapeutics4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12736.90 millionN/ANot OptionableBTMDbiote19454.71 million41.58 millionNot OptionableELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionableLRMRLarimar Therapeutics3064.03 million61.15 millionOptionableANL, BTMD, LRMR, and ELDN HeadlinesRecent News About These CompaniesLarimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesJuly 31 at 4:15 PM | globenewswire.comLarimar Therapeutics shares drop following $60 million public offeringJuly 30 at 1:24 PM | msn.comLarimar Therapeutics (LRMR) Expected to Announce Quarterly Earnings on WednesdayJuly 30 at 3:47 AM | marketbeat.comLarimar Therapeutics Announces Pricing of Underwritten Public OfferingJuly 29, 2025 | globenewswire.comLarimar Therapeutics, Inc. Announces Pricing of $60 Million Public Offering of Common StockJuly 29, 2025 | quiverquant.comQLarimar Therapeutics Announces Proposed Underwritten Public OfferingJuly 29, 2025 | globenewswire.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives $18.50 Consensus PT from BrokeragesJuly 29, 2025 | americanbankingnews.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by BrokeragesJuly 26, 2025 | marketbeat.com5 Small Drug Stocks to Buy Amid Trump's New Tariff ThreatsJuly 16, 2025 | zacks.comLarimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's AtaxiaJuly 8, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Larimar Therapeutics (LRMR)June 24, 2025 | theglobeandmail.comLarimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia ProgramJune 23, 2025 | globenewswire.comLarimar Therapeutics to Host Conference Call on Regulatory Updates for Nomlabofusp Clinical Development ProgramJune 22, 2025 | nasdaq.comLarimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s AtaxiaJune 20, 2025 | finance.yahoo.comLarimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's AtaxiaJune 20, 2025 | globenewswire.comLarimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stockMay 24, 2025 | investing.comLarimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside PotentialMay 21, 2025 | insidermonkey.comWhy Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 6.40%May 6, 2025 | aaii.comALarimar Therapeutics Advances Nomlabofusp Amid Financial LossMay 4, 2025 | tipranks.comLarimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp DevelopmentMay 4, 2025 | msn.comLarimar Therapeutics Reports First Quarter 2025 Financial ResultsApril 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonBig Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadBy Gabriel Osorio-Mazilli | July 3, 2025View Big Bank Buybacks: Morgan Stanley, Citi, & Wells Fargo LeadBig 3 Telecom Wars: 2 Solid Showings, 1 Huge Winner in Q2By Leo Miller | July 29, 2025View Big 3 Telecom Wars: 2 Solid Showings, 1 Huge Winner in Q2Goldman, Morgan Stanley, & BofA: Diverging Paths After EarningsBy Sam Quirke | July 21, 2025View Goldman, Morgan Stanley, & BofA: Diverging Paths After EarningsANL, BTMD, LRMR, and ELDN Company DescriptionsAdlai Nortye NASDAQ:ANL$1.46 +0.03 (+1.75%) Closing price 08/1/2025 03:57 PM EasternExtended Trading$1.46 0.00 (0.00%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.biote NASDAQ:BTMD$3.89 -0.18 (-4.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.89 0.00 (0.00%) As of 08/1/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Eledon Pharmaceuticals NASDAQ:ELDN$3.38 +0.23 (+7.30%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.53 +0.15 (+4.44%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Larimar Therapeutics NASDAQ:LRMR$3.44 -0.02 (-0.58%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.49 +0.05 (+1.45%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
